Previous 10 | Next 10 |
MENDHAM, N.J. and WARMINSTER, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis...
Arena Pharmaceuticals (NASDAQ:ARNA) +90% on acquisition by Pfizer. Foghorn Therapeutics (NASDAQ:FHTX) +38% after collaborating with Lilly in oncology medicines. BELLUS Health (NASDAQ:BLU) +36% on positive BLU-5937 data in mid-stage chronic cough study. Petros Pha...
Arbutus Biopharma (NASDAQ:ABUS) and Qilu Pharmaceutical have brokered a licensing agreement and partnership for the former's AB-729 for hepatitis B ("HBV") in China, Hong Kong, Macau, and Taiwan. Terms call for Arbutus to receive $40M upfront and a $15M equity investment. The company is ...
Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong Kong, Macau and Taiwan markets Arbutus to receive $40 million in an upfront pay...
4 Penny Stocks Under $5 to Watch in December 2021 Making a list of the best penny stocks to buy in December? Well, there are plenty of options to choose from. The first step as an investor is to understand what type of trader you are and what your tolerance for risk is. On one hand, we ...
Why These 4 Penny Stocks on Reddit Are Popular in December Right now, trading penny stocks is extremely popular. And, this has been the case for several years now, as more and more investors discover the potential that penny stocks have to offer. While either penny stocks or blue ...
Penny Stocks To Buy According To 4 Analysts Right Now If you’re looking for penny stocks to buy, you might be looking for specific trends. We’ve covered many of these over the last few weeks. Whether it’s stocks with low floats, penny stocks with high short inte...
Arbutus Biopharma (NASDAQ:ABUS) has reportedly identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), which are said to be a validated target in the treatment of COVID-19 and future outbreaks of the disease. Following the discovery, the company has obtained a worl...
Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, Pa. and WALTHAM, Mass. and MUNICH, Germany, Dec. 07, 2021 (GLOBE NEWS...
CF Acquisition (NASDAQ:CFVIU) +28% on deal to take conservative video platform Rumble public Phunware (NASDAQ:PHUN) +23%. Digital World Acquisition (NASDAQ:DWAC) +23% on deal to take conservative video platform Rumble public Omeros (NASDAQ:OMER) +18% to sell OMID...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...